Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
Add to list
  1. Search results
  2. Feasibility of radiotherapy with conc...

Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study

Stéphanie Laurent (UGent) , Els Monsaert, Tom Boterberg (UGent) , A Demols, I Borbath, M Polus, A Hendlisz, Bernard de Hemptinne (UGent) , C Mahin, P Scalliet, et al.
(2009) ANNALS OF ONCOLOGY. 20(8). p.1369-1374
Author
Organization
Abstract
Patients and methods: Twenty-two patients with locally advanced pancreatic (n = 17) or biliary tract cancer (n = 5) were included. They received two cycles of gemcitabine/oxaliplatin followed by 5 weeks of RT in combination with a weekly fixed dose gemcitabine and an escalating dose of oxaliplatin from 40 up to 70 mg/m(2). National Cancer Institute-Common Toxicity Criteria 3.0 was used to score weekly the treatment-related toxicity. Results: The patients treated at a dose of 40 mg/m(2) of oxaliplatin had no dose-limiting toxicity. At 50 mg/m(2), two patients developed grade 4 thrombocytopenia. Nine patients received 60 mg/m(2), one developed grade 4 thrombocytopenia. Grade 4 thrombocytopenia in two patients and grade 3 diarrhea in one patient were observed with 70 mg/m(2). Median time to progression was 8 months and median overall survival was 17 months. Conclusions: RT in combination with gemcitabine and oxaliplatin is feasible in patients with locally advanced pancreaticobiliary cancer. The reported time to progression underlines the potential activity of this regimen. The dose of 60 mg/m(2) of oxaliplatin can be considered as the recommended dose.

Citation

Please use this url to cite or link to this publication:

MLA
Laurent, Stéphanie, et al. “Feasibility of Radiotherapy with Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma: A Prospective Dose Finding Phase I-II Study.” ANNALS OF ONCOLOGY, vol. 20, no. 8, 2009, pp. 1369–74, doi:10.1093/annonc/mdp005.
APA
Laurent, S., Monsaert, E., Boterberg, T., Demols, A., Borbath, I., Polus, M., … Peeters, M. (2009). Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study. ANNALS OF ONCOLOGY, 20(8), 1369–1374. https://doi.org/10.1093/annonc/mdp005
Chicago author-date
Laurent, Stéphanie, Els Monsaert, Tom Boterberg, A Demols, I Borbath, M Polus, A Hendlisz, et al. 2009. “Feasibility of Radiotherapy with Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma: A Prospective Dose Finding Phase I-II Study.” ANNALS OF ONCOLOGY 20 (8): 1369–74. https://doi.org/10.1093/annonc/mdp005.
Chicago author-date (all authors)
Laurent, Stéphanie, Els Monsaert, Tom Boterberg, A Demols, I Borbath, M Polus, A Hendlisz, Bernard de Hemptinne, C Mahin, P Scalliet, JL Van Laethem, and Marc Peeters. 2009. “Feasibility of Radiotherapy with Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma: A Prospective Dose Finding Phase I-II Study.” ANNALS OF ONCOLOGY 20 (8): 1369–1374. doi:10.1093/annonc/mdp005.
Vancouver
1.
Laurent S, Monsaert E, Boterberg T, Demols A, Borbath I, Polus M, et al. Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study. ANNALS OF ONCOLOGY. 2009;20(8):1369–74.
IEEE
[1]
S. Laurent et al., “Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study,” ANNALS OF ONCOLOGY, vol. 20, no. 8, pp. 1369–1374, 2009.
@article{824749,
  abstract     = {{Patients and methods: Twenty-two patients with locally advanced pancreatic (n = 17) or biliary tract cancer (n = 5) were included. They received two cycles of gemcitabine/oxaliplatin followed by 5 weeks of RT in combination with a weekly fixed dose gemcitabine and an escalating dose of oxaliplatin from 40 up to 70 mg/m(2). National Cancer Institute-Common Toxicity Criteria 3.0 was used to score weekly the treatment-related toxicity.

Results: The patients treated at a dose of 40 mg/m(2) of oxaliplatin had no dose-limiting toxicity. At 50 mg/m(2), two patients developed grade 4 thrombocytopenia. Nine patients received 60 mg/m(2), one developed grade 4 thrombocytopenia. Grade 4 thrombocytopenia in two patients and grade 3 diarrhea in one patient were observed with 70 mg/m(2). Median time to progression was 8 months and median overall survival was 17 months.

Conclusions: RT in combination with gemcitabine and oxaliplatin is feasible in patients with locally advanced pancreaticobiliary cancer. The reported time to progression underlines the potential activity of this regimen. The dose of 60 mg/m(2) of oxaliplatin can be considered as the recommended dose.}},
  author       = {{Laurent, Stéphanie and Monsaert, Els and Boterberg, Tom and Demols, A and Borbath, I and Polus, M and Hendlisz, A and de Hemptinne, Bernard and Mahin, C and Scalliet, P and Van Laethem, JL and Peeters, Marc}},
  issn         = {{0923-7534}},
  journal      = {{ANNALS OF ONCOLOGY}},
  language     = {{eng}},
  number       = {{8}},
  pages        = {{1369--1374}},
  title        = {{Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study}},
  url          = {{http://doi.org/10.1093/annonc/mdp005}},
  volume       = {{20}},
  year         = {{2009}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: